1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity

Q: What does this research mean for the field?

1,2,4-Triazolo[4,3-c]quinazolines, developed through a bioisosterism-guided approach, act as novel PCAF inhibitors with potential anticancer activity. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Mohamed H. El‐Shershaby; Adel Ghiaty; Ashraf H. Bayoumi; Hany E. A. Ahmed; Mona S. El‐Zoghbi; Khaled El‐Adl; Hamada S. Abulkhair

doi:10.1039/d1nj00710f

January 1, 2021New Journal of Chemistry

1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Targeting PCAF with small inhibitor molecules has emerged as a potential therapeutic strategy for the treatment of cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

El‐Shershaby et al. (2021) studied this question.

synapsesocial.com/papers/6a23fc3d4e3df5db62a5f0b1 https://doi.org/10.1039/d1nj00710f

View at Publisher

Ask AI

Bookmark

Share

1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity

Ask about this paper

Abstract

Discussion

Cite This Study

1,2,4-Triazolo[4,3-c]quinazolines: a bioisosterism-guided approach towards the development of novel PCAF inhibitors with potential anticancer activity

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading